| Related Articles |
The second ASH choosing wisely campaign: five hematologic tests and treatments to question.
Blood. 2014 Dec 3;
Authors: Hicks LK, Bering H, Carson KR, Haynes AE, Kleinerman J, Kukreti V, Ma A, Mueller BU, O'Brien SH, Panepinto JA, Pasquini MC, Rajasekhar A, Sarode R, Wood WA
Abstract
Choosing Wisely is a medical stewardship initiative led by the American Board of Internal Medicine Foundation in collaboration with professional medical societies in the United States. The American Society of Hematology (ASH) released its first Choosing Wisely list in 2013. Using the same evidence-based methodology as in 2013, ASH has identified five additional tests and treatments which should be questioned by clinicians and patients under specific, indicated circumstances. The ASH 2014 Choosing Wisely recommendations include: Don't anti-coagulate for more than three months in patients experiencing a first venous thromboembolic event (VTE) in the setting of major, transient risk factors for VTE; don't routinely transfuse for chronic anemia or uncomplicated pain crises in patients with sickle cell disease; don't perform baseline or surveillance CT scans in patients with asymptomatic, early stage CLL; don't test or treat for heparin induced thrombocytopenia (HIT) if the clinical pretest probability of HIT is low; and don't treat patients with immune thrombocytopenia (ITP) unless they are bleeding or have very low platelet counts.
PMID: 25472968 [PubMed - as supplied by publisher]